Literature DB >> 23788321

Growth and development of a new subspecialty: pediatric hepatology.

William F Balistreri1.   

Abstract

Several major forces converged to catalyze the formal emergence of a body of knowledge and an organized focus on disorders of the liver in early life. Attendant to the development of a focused clinical subspecialty the pace of patient- and laboratory-based research in the field quickened in parallel to decipher the consequences of genetic or metabolic aberrations on immature liver structure and function. The key research observations that catalyzed the emergence and subsequent rapid growth of Pediatric Hepatology include: (1) an understanding of the dynamic events occurring during hepatobiliary development and the importance of these physiologic variables that occur during liver maturation; (2) the recognition of the unique nature of inherited and acquired liver diseases that affect infants and children-such as biliary atresia and Reye's syndrome; and (3) redefinition of the once obscure inherited intrahepatic cholestatic diseases of the liver, which, in turn, provided insight into normal and abnormal hepatobiliary physiology. The clinical advances were highlighted by the development of specific approaches to the diagnosis and management of liver disease in infants and children, including both liver transplantation and nontransplant treatment options. These seminal events led to the expansion of the workforce, creating a critical mass consisting of individuals with focused, specialized skills and techniques. In-depth expertise allowed more accurate diagnosis and highly effective treatment strategies for advanced hepatobiliary disease in children. The demand for pediatric clinicians with experience in advanced hepatology allowed sub-sub-specialization to flourish. Continued maturation of the field led to definition of hepatology-focused curricular elements and educational content for Pediatric Gastroenterology training programs, and subsequently the development of program requirements for those who wished to acquire additional training in Pediatric Hepatology. A significant rite of passage was marked by the election of pediatric hepatologists to leadership positions in the American Association for the Study of Liver Diseases (AASLD). Further validation of the field occurred with approval of the petition for establishing a Certificate of Added Qualification in Transplant Hepatology by the American Board of Pediatrics. Here I relate my perspective on the history of the advances in our field and the contributions of many of the clinicians and scientists whose efforts led to the development of focused clinical, research, and training programs that improved the care of children with diseases of the liver.
Copyright © 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23788321     DOI: 10.1002/hep.26580

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  Patterns of Change in ACGME-Accredited Residency Programs and Positions: Implication for the Adequacy of GME Positions and Supply of Physicians in the United States.

Authors:  Kathleen D Holt; Rebecca S Miller; Ingrid Philibert; Thomas J Nasca
Journal:  J Grad Med Educ       Date:  2014-06

2.  Training in pediatric hepatology across Europe: a survey of the National Societies Network (2016-2019) of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Alexandra Papadopoulou; Carmen Ribes-Koninckx; Maria Noni; Eleni Koutri; Maria-Vasiliki Karagianni; Sue Protheroe; Alfredo Guarino; Emmanuel Mas; Michael Wilschanski; Enriqueta Roman; Johanna Escher; Raoul I Furlano; Carsten Posovszky; Ilse Hoffman; Gabor Veres; Jiri Bronsky; Almuthe Christine Hauer; Duska Tjesic-Drinkovic; Maria Fotoulaki; Rok Orel; Vaidotas Urbonas; Aydan Kansu; Miglena Georgieva; Alastair Baker; Deirdre Kelly
Journal:  Ann Gastroenterol       Date:  2022-02-14

3.  Functional characterization of ABCB4 mutations found in progressive familial intrahepatic cholestasis type 3.

Authors:  Hyo Jin Park; Tae Hee Kim; So Won Kim; Shin Hye Noh; Kyeong Jee Cho; Choe Choi; Eun Young Kwon; Yang Ji Choi; Heon Yung Gee; Ji Ha Choi
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

4.  Liver disease referrals to an urban, hospital-based hepatology outpatient clinic over the past 25 years.

Authors:  Micah Grubert Van Iderstine; Daniel Iluz-Freundlich; Casandra Dolovich; Eurielle Villarin; Gerald Y Minuk
Journal:  JGH Open       Date:  2019-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.